Although a single case can only be the basis for further investigation, together with the preclinical studies below, the data suggest that sub-sets of hepatocellular carcinomas with specific molecular aberrations could be candidates for treatment with CDK4/6 inhibitors, in combination with other relevant targeted therapies. This evidence concerns the gene CDK4 and hepatocellular carcinoma.